MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD
出版年份 2015 全文链接
标题
MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD
作者
关键词
-
出版物
IUBMB LIFE
Volume 67, Issue 3, Pages 191-201
出版商
Wiley
发表日期
2015-04-15
DOI
10.1002/iub.1361
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Drug resistance-related microRNAs in hematological malignancies: Translating basic evidence into therapeutic strategies
- (2015) Lingling Xie et al. BLOOD REVIEWS
- Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494
- (2015) Yifeng Bai et al. Oncotarget
- MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study
- (2014) Augusto LF Marino et al. BMC CANCER
- Overexpression of MicroRNA-122 Re-sensitizes 5-FU-Resistant Colon Cancer Cells to 5-FU Through the Inhibition of PKM2 In Vitro and In Vivo
- (2014) Jinxia He et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc
- (2014) Weiling He et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression
- (2014) V. J. Findlay et al. MOLECULAR CANCER THERAPEUTICS
- MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer
- (2014) Peng-fei Shen et al. PROSTATE
- Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic Regimens
- (2014) Yingjie Yu et al. Translational Oncology
- p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
- (2014) Valentina Grossi WORLD JOURNAL OF GASTROENTEROLOGY
- Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
- (2014) Mariusz Panczyk WORLD JOURNAL OF GASTROENTEROLOGY
- Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer
- (2014) Ingrid Garajová et al. Biomed Research International
- MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer
- (2013) Lionel Lim et al. HEPATOLOGY
- Differential Clinical Benefits of 5-Fluorouracil-based Adjuvant Chemotherapy for Patients with Stage III Colorectal Cancer According to CD133 Expression Status
- (2013) A. Shikina et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases
- (2013) Christoph Reissfelder et al. SURGERY
- Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements
- (2013) Eddie K. Abdalla et al. HPB
- Chemotherapy-Associated Liver Injury in Patients with Colorectal Liver Metastases: A Systematic Review and Meta-analysis
- (2012) Stuart M. Robinson et al. ANNALS OF SURGICAL ONCOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer
- (2012) Jose J. G. Marin et al. DRUG METABOLISM REVIEWS
- Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
- (2011) J. Cassidy et al. ANNALS OF ONCOLOGY
- MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation
- (2011) W. K. Kim et al. CLINICAL CANCER RESEARCH
- MicroRNAs: Target Recognition and Regulatory Functions
- (2009) David P. Bartel CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More